Evotec SE Annual General Meeting 2025: An Overview
On June 3, 2025, Evotec SE held its annual general meeting under the motto “Pioneering Drug Discovery.” This event provided important insights into the strategic orientation and future developments of the company in a dynamic market environment.
Results of the General Meeting
- Agenda Items: All proposals were accepted, including the discharge of the executive board and supervisory board members for the fiscal year 2024 as well as the approval of the remuneration report.
- Virtual General Meetings: The articles of association were amended to allow for virtual general meetings, making communication with shareholders more flexible.
- Auditor: BDO AG Wirtschaftsprüfungsgesellschaft was confirmed as the auditor for the fiscal year 2025.
- Strategic Outlook: CEO Dr. Christian Wojczewski presented the innovation strategy in drug research.
- Shareholder Participation: 46.45% of the capital was represented, a sign of strong shareholder involvement.
Importance for Investors
The meeting underscores Evotec’s commitment to innovation in drug research. The move to virtual general meetings and the stable financial situation are critical for the company’s future. These factors position Evotec as a key player in global drug research.
Moreover, the strong shareholder participation conveys confidence in the company’s strategic measures.